Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ: AVIR )

3.195 -0.075 (-2.29%)
Streaming Delayed Price Updated: 12:31 PM EST, Jan 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 Next >
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy
Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for 
Via Benzinga
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals's Earnings Outlook
Via Benzinga
Earnings Preview For Atea Pharmaceuticals
Via Benzinga
Earnings Preview: Atea Pharmaceuticals
Via Benzinga
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Via Benzinga
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
Combination Offers Opportunity to Improve Standard of Care with Potential for Short Duration, Protease Inhibitor-Free Treatment 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy. 
Via Benzinga
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
Proposal Fundamentally Undervalues Atea; Not in the Best Interests of Atea or Its Shareholders 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Biotech Bargain Hunt: Concentra Biosciences Eyes Atea's Promising COVID-19 Response
Earlier today, Concentra Biosciences, an affiliate of Tang Capital, sent an acquisition proposal to Atea Pharmaceuticals Inc (NASDAQ: AVIR) at $5.75 per share, representing a 55% premium to Friday’s... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share. 
Via Benzinga
Atea Pharmaceuticals Inc. (NASDAQ: AVIR) Highlighted for Surprising Price Action
Via Investor Brand Network
Exposures COVID-19
US Stocks Mixed; Nordic American Tankers Posts Upbeat Results
U.S. stocks traded mixed this morning, with the Dow Jones trading slightly lower on Monday. Following the market opening Monday, the Dow traded down 0.01% to 33,422.94 while the NASDAQ rose 0.09% to... 
Via Benzinga
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.